Pipeline Vantage Embolization Device with Shield Technology
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · Decision date Aug 14, 2025
What did the FDA approve?
FDA records P100018/S048 as a supplement to PMA P100018, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 14, 2025.
FDA approval order statement
Approval for changes to the post-approval study (PAS) protocol for Pipeline Vantage device following the removal of the Vantage 027 devices, including updates to include additional follow-up imaging to assess for braid deformation events.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Aug 14, 2025
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P100018/S048
- Regulatory pathway
- PMA supplement
- Product code
- OUT
- Decision code
- APPR
- Decision date
- Aug 14, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intracranial aneurysm flow diverter.
- Product code
- OUT
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100018/S048 received
Application receipt date recorded by FDA.
P100018/S048 · FDA decision
Normal 180 Day Track No User Fee
P100018/S052 · Related supplement
PIPELINE EMBOLIZATION DEVICE
P100018/S053 · Related supplement
Pipeline Flex Embolization Device (Pipeline Flex); Pipeline Flex Embolization Device with Shield Technology (Pipelin
P100018/S054 · Related supplement
Pipeline Flex Embolization Device with Shield Technology (Pipeline Shield); Pipeline Vantage Embolization Device wit
P100018/S055 · Related supplement
Pipeline Flex Embolization Device (Pipeline Flex); Pipeline Flex Embolization Device with Shield Technology (Pipelin
Timeline entries are records held by MedtechLedger for P100018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PIPELINE EMBOLIZATION DEVICEP100018/S052 | Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Feb 20, 2026 | FDA |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | May 15, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jun 26, 2026 | FDA | |
| Micro Therapeutics, Inc. d/b/a ev3 Neurovascular | PMA supplement | Jul 21, 2026 | FDA |
Explore the linked device profile
Other records with product code OUT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Surpass Elite Flow DiverterP170024/S027 | Stryker Neurovascular | PMA supplement | Aug 28, 2026 | FDA |
Surpass Evolve; Surpass Elite FDSP170024/S026 | Stryker Neurovascular | PMA supplement | Jun 26, 2026 | FDA |
| Microvention, Inc. | PMA supplement | Nov 2, 2025 | FDA | |
| Microvention, Inc. | PMA supplement | Sep 20, 2025 | FDA | |
FRED X SystemP180027/S014 | Microvention, Inc. | PMA supplement | Sep 18, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P100018/S048
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





